ASX healthcare served up a week with more than a few head-scratchers. Pic: Getty Images<\/p>\n
Paradigm\u2019s phase III knee osteoarthritis trial has failed its interim efficacy test
\nTelix strikes $3.3 billion merger deal with Germany\u2019s ITM Isotope Technologies Munich
\nMicroba Life Sciences and Genetic Signatures have agreed to merge in a proposed scheme of arrangement<\/p>\n
\u00a0<\/p>\n
Healthcare and life sciences expert Scott Power, a senior analyst at Morgans Financial for 29 years, and his team share their insights on the ASX healthcare sector for the week.<\/p>\n
\u00a0<\/p>\n
It\u2019s been a big week of news for the ASX healthcare sector, which has lifted again despite a traditionally soft September, with a failed phase III trial and proposed mergers among the highlights.<\/p>\n
The XHJ has moved up 0.86% over the past five days, while the benchmark S&P\/ASX 200 (ASX:XJO) is down 0.32%.<\/p>\n
\u201cThe Australian healthcare sector traded largely sideways this week, reflecting a balance between company-specific wins and setbacks,\u201d Power said.<\/p>\n
\u00a0<\/p>\n
Paradigm\u2019s phase III trial fails interim efficacy test<\/p>\n
Paradigm Biopharmaceuticals\u2019 (ASX:PAR)<\/a> phase III knee osteoarthritis trial has failed its interim efficacy test, with the company saying significant missing data impacted the result.<\/p>\n In an ASX announcement<\/a> PAR said the 538-patient PARA-OA-012 trial of Zilosul (injectable pentosan polysulphate sodium) \u201cdid not reach the pre-specified threshold required for the study to continue\u201d, following an assessment by an independent data safety monitoring board.<\/p>\n PAR said operational challenges during the trial resulted in a \u201csignificant amount of missing data\u201d, which impacted the interim efficacy results.<\/p>\n The company continues to review the available data to better understand the nature and extent of that impact.<\/p>\n The interim analysis covered 50% of participants at day 112 of treatment. Based on the result, the trial is unlikely to meet its primary efficacy endpoint in the final analysis, which was due in the March 2027 quarter.<\/p>\n PAR is also assessing the financial and operational implications of the outcome, including its funding arrangements with Obsidian Global Partners.<\/p>\n The company said it retains a \u201csubstantial intellectual property portfolio\u201d and is assessing the most appropriate path forward.<\/p>\n PAR has requested that its securities remain in voluntary suspension until it can release a further announcement addressing the financial and funding implications of the trial outcome, which is expected by September 28.<\/p>\n \u201cWe will have to wait until Paradigm resumes trading and provides an update on the trial and funding arrangements,\u201d Power said.<\/p>\n \u00a0<\/p>\n Telix strikes $3.3 billion merger deal<\/p>\n Telix Pharmaceuticals (ASX:TLX)<\/a> has unveiled a proposed merger with private German radiopharma company ITM Isotope Technologies Munich valued at up to $3.3 billion.<\/p>\n Under the proposed deal TLX will acquire 100% of ITM for US$1.65 billion ($2.35 billion) upfront, comprising $1.75bn in TLX shares and the assumption of about $424 million in ITM net debt.<\/p>\n A further US$700 million (~$980m) could be payable if ITM-11 hits specified regulatory and sales milestones.<\/p>\n ITM is a major supplier of therapeutic radioisotopes including lutetium-177, actinium-225 and terbium-161, with a global distribution network spanning more than 65 countries.<\/p>\n The company generated US$273m ($383m) in revenue in 2025 and operates a profitable isotope manufacturing business.<\/p>\n The deal also brings ITM-11 (lutetium-177-edotreotide), a late-stage treatment for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), into TLX\u2019s pipeline.<\/p>\n ITM-11 has completed one phase III trial, while a second phase III study is fully enrolled with an interim analysis expected in the first half of 2027.<\/p>\n The combined group is expected to generate pro forma 2026 revenue and income exceeding US$1.3 billion, according to management estimates.<\/p>\n The transaction is subject to TLX shareholder and regulatory approval, with completion targeted by the end of 2026.<\/p>\n \u201cThis is a strategically significant acquisition that strengthens Telix\u2019s isotope supply chain, expands its therapeutic portfolio, and accelerates its ambition to become a global leader in radiopharmaceuticals,\u201d Power said.<\/p>\n \u00a0<\/p>\n Microba, Genetic Signatures plan merger<\/p>\n Microba Life Sciences (ASX:MAP)<\/a> and Genetic Signatures (ASX:GSS)<\/a> have agreed to merge, creating a combined diagnostics group with annual revenue pushing $30 million.<\/p>\n \u201cThe proposed merger will bring together two established Australian diagnostics businesses with complementary technologies, products and international distribution networks to create a larger and stronger combined ASX-listed diagnostics group,\u201d the companies said.<\/p>\n Under the proposed scheme of arrangement, GSS will acquire 100% of MAP. Under the terms, MAP shareholders would receive 0.654 new GSS shares for every MAP share.<\/p>\n MAP shareholders would own 67% of the enlarged group, with existing GSS shareholders holding 33%. The proposed ownership split reflects the relative market capitalisations of the two companies, with MAP valued at ~$35.8m and GSS at ~$18m.<\/p>\n The proposal first requires GSS shareholder approval before the companies execute a Scheme Implementation Deed. MAP shareholders would later vote on the scheme itself, which would also require court approval.<\/p>\n There is another complication to the proposed merger, with breast cancer diagnostics company BCAL Diagnostics having amassed an 18.5% stake in GSS and wanting to remove certain directors.<\/p>\n \u201cA board spill mid-Scheme raises genuine risk to the deal proceeding,\u201d Morgans healthcare analyst Ian Wilkie wrote in a research note.<\/p>\n GSS has developed its proprietary 3base molecular diagnostic technology, which underpins its EasyScreen range of PCR tests for rapid gut, respiratory and other infectious pathogens.<\/p>\n MAP provides clinical gut microbiome testing to healthcare professionals in Australia and the UK.<\/p>\n Wilkie wrote the proposed merger removed some uncertainty but also introduced new risks for MAP shareholders.<\/p>\n \u201cPlenty more to come on the merger front but in terms of pure MAP view \u2013 we think it muddies the case on two fronts,\u201d he wrote.<\/p>\n \u201cThe standalone breakeven story was clean, this resets it and adds integration risk.<\/p>\n \u201cThe board that struck these terms is itself under attack, so there\u2019s real doubt the terms survive to execution. Conviction lower near-term pending clarity on the GSS board outcome.\u201d<\/p>\n Morgans has a speculative buy on MAP and 12-month price target of 12 cents.<\/p>\n \u00a0<\/p>\n Sonic faces another US headwind<\/p>\n Sonic Healthcare (ASX:SHL)<\/a> is facing another headwind in its US pathology business after the US Centers for Medicare & Medicaid Services (CMS) released preliminary Calendar Year 2027 Clinical Laboratory Fee Schedule (CLFS) rates.<\/p>\n Morgans healthcare analyst Derek Jellinek wrote in a research note that the latest rates will see most Medicare laboratory test payments moving towards private-payor rates.<\/p>\n \u201cThe preliminary data implied an average reduction of about 16% across affected codes, although the statutory 15% annual reduction cap means the impact will be phased through CY27-29,\u201d he wrote.<\/p>\n Jellinek wrote that while the preliminary CLFS rates were a negative development and added to existing pressures including Swiss fee reductions, Australian wage increases and higher UK costs, the impact appeared manageable.<\/p>\n He wrote SHL had previously flagged a potential $15m FY27 impact, which was immaterial to the group, and was excluded from its $1.95 billion to $2.03bn FY27 EBITDA guidance.<\/p>\n The US business generated $2.05bn of revenue in FY26, about 19% of group revenue, with Morgans forecasting FY27 US EBITDA of ~$310m.<\/p>\n Jellinek estimates the $15m fee impact would reduce US EBITDA by ~5%, but group EBITDA by less than 1%, although the final impact will depend on SHL\u2019s test mix and the final rates.<\/p>\n The reimbursement pressure comes as SHL undertakes an operational review of its US business.<\/p>\n Jellinek noted nine anatomical pathology practices have been rationalised, alongside procurement savings, a 10% reduction in corporate headcount and centralisation of corporate functions.<\/p>\n The initiatives completed or underway are expected to add $25m to $30m to FY27 earnings.<\/p>\n Final rates are expected in November following a 30-day consultation period and will take effect from January 1, 2027.<\/p>\n Morgans has a hold rating on Sonic with a 12-month price target of $22.40.<\/p>\n \u00a0<\/p>\n Ramsay demerger of European business remains on track<\/p>\n